◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY
Summit Therapeutics Inc. (SMMT) Revenue 2021–2025
DATA UPDATED 2026-07-10
Summit Therapeutics Inc. annual revenue for fiscal 2025 was $0 million, compared with $0 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
SMMT Annual Revenue
| Revenue (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|
| Total Revenue | $0M | $0M | $0M | $1M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
SMMT Quarterly Revenue
| Revenue (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More SMMT metrics: Operating Income · Net Income · EPS · Free Cash Flow
All SMMT financial statements → Interactive SMMT charts →
About TickerBase · Data methodology & sources
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.